Skip to main content

Advertisement

SpringerLink
Log in

Long-lasting dermatological lesions after tiludronate therapy

  • Rapid Communication
  • Published:
Calcified Tissue International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fleish H (1989) Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 116:1–28

    Google Scholar 

  2. Fels JP, Guyonnet J, Berger Y, Cautreels W (1988) Determination of SR 41319, a new bisphosphonate in biological fluids by high-performance liquid chromatography. J Chromatogr 430:73–79

    Google Scholar 

  3. Guillaume JC, Roujeau JC, Chevrant-Breton J, Revuz J, Souteyrand P, Albengres E, Begaud B, Benichou C, Danan G, Evreux JC, Kreft-Jais C (1987) Comment imputer un accident cutané à un médicament. Ann Dermatol Venerol 114:721–724

    Google Scholar 

  4. Rules and regulation (1987) Federal Register 52: 8837.

    Google Scholar 

  5. Mautalen CA, Casco CA, Gonzalez D, Ghiringhelli GR, Massironi C, Fromm GA, Plantalech L (1984) Side effects of disodium aminohydroxypropylidene-diphosphonate (APD) during treatment of bone diseases, Br Med J 288:828–829

    Google Scholar 

  6. Collins MR, James WD, Rodman OG (1988) Adverse cutaneous reaction to technetium Tc 99m methylene diphosphonate. Arch Dermatol 124:180–181

    Google Scholar 

  7. Ramos-Gabatin A, Orzel JA, Maloney TR, Murnane JE, Borcher RD (1986) Severe systemic reaction to diphosphonate bone imaging agents: skin testing to predict allergic response and a safe alternative agent. J Nucl Med 27:1432–1435

    Google Scholar 

  8. Elliot AT, Murray T, Mackie RM, Hunter JA (1988) Severe reaction to diphosphonate: implications for treatment of Paget's disease. Br Med J 297:592–593

    Google Scholar 

  9. Reginster JY, Deroisy R, Denis D, Collette J, Lecart MP, Sarlet N, Ethgen D, Franchimont P (1989) Prevention of post menopausal bone loss by tiludronate. Lancet 2:1469–1471

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, René Descartes University, Cochin Hospital, Paris, France

    C. Roux, V. Listrat, M. Dougados & B. Amor

  2. Department of Dermatology, René Descartes University, Cochin Hospital, Paris, France

    B. Villette & M. Lessana-Leibowitch

  3. Amgop, Paris, France

    C. Pelissier

  4. Sanofi Research, Montpellier, France

    D. Ethgen

Authors
  1. C. Roux
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Listrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Villette
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Lessana-Leibowitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. Ethgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Pelissier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Dougados
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Amor
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Roux, C., Listrat, V., Villette, B. et al. Long-lasting dermatological lesions after tiludronate therapy. Calcif Tissue Int 50, 378–380 (1992). https://doi.org/10.1007/BF00301637

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00301637

Keywords

Search

Navigation